Market Overview

Hemispherx Biopharma Says FDA Panel Voted 9-4 Against Ampligen Effocacy

Share:
Related HEB
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
Are There Any Small Biotechnology Companies With An Answer To The Zika Virus Question? (Seeking Alpha)

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced the outcome of the meeting of the Arthritis Advisory Committee (the "AAC") of the U.S. Food and Drug Administration (the "FDA") on the New Drug Application ("NDA") for Ampligen^® for Chronic Fatigue Syndrome ("CFS").

On the question: "Considering the totality of the data, is there substantial evidence of efficacy for Ampligen for the treatment of patients with chronic fatigue syndrome (CFS)?," the AAC voted 9 no, 4 yes and 1 AAC member left the room and did not vote.

Posted-In: News FDA

 

Related Articles (HEB)

View Comments and Join the Discussion!

Get Benzinga's Newsletters